Claims
- 1. A method for combating urinary tract dysfunction in a subject comprising administering to the subject an effective amount of a delta opioid receptor agonist to combat the urinary tract dysfunction, wherein the delta opioid receptor agonist is selected from the group consisting of:
- 2. The method according to claim 1, wherein the delta opioid receptor agonist is administered in a pharmaceutical composition comprising the delta opioid receptor agonist, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.
- 3. The method according to claim 2, wherein the composition is administered by an administration modality selected from the group consisting of oral, rectal, vaginal, topical, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, and intra-uterine administration.
- 4. The method according to claim 3, wherein the composition is administered in a unitary dose form.
- 5. The method according to claim 2, wherein the pharmaceutical composition for treating the urinary tract dysfunction, further comprises at least one additional active agent that treats the urinary tract dysfunction.
- 6. The method according to claim 5, wherein the active agent is selected from the group consisting of: an alpha-adrenergic agonist, an anticholinergic, an alpha-adrenergic antagonist and a tricyclic antidepressant.
- 7. The method according to claim 1, wherein the urinary tract dysfunction comprises urinary incontinence.
- 8. A pharmaceutical composition for combating urinary tract dysfunction comprising: a delta opioid receptor agonist in an effective amount to combat the urinary tract dysfunction, wherein the delta opioid receptor agonist is selected from the group consisting of:
- 9. A pharmaceutical unit dosage form for treating a urinary tract dysfunction comprising a delta opioid receptor agonist according to claim 8, wherein said pharmaceutical unit dosage form is selected from the group consisting of: a tablet, a soft elastic gelatin capsule, a transdermal patch and a suppository.
- 10. The pharmaceutical composition according to claim 8, further comprising at least one additional active agent that treats the urinary tract dysfunction.
- 11. The pharmaceutical composition according to claim 10, wherein the active agent is selected from the group consisting of: an alpha-adrenergic agonist, an anticholinergic, an alpha-adrenergic antagonist and a tricyclic antidepressant.
- 12. The pharmaceutical composition according to claim 8, wherein the urinary tract dysfunction comprises urinary incontinence.
- 13. A kit for combating a urinary tract dysfunction, comprising:
an effective amount of a delta opioid receptor agonist to combat the urinary tract dysfunction, wherein the delta opioid receptor agonist is selected from the group consisting of: 6163264365466567668769870971107211731274and pharmaceutically acceptable salts and esters thereof.
- 14. The kit according to claim 13, further comprising at least one additional active agent used to combat a urinary tract dysfunction selected from the group consisting of: an alpha-adrenergic agonist, an anticholinergic, an alpha-adrenergic antagonist and a tricyclic antidepressant.
- 15. A method for combating a urinary tract dysfunction in a subject comprising administering to the subject an effective amount of a delta opioid receptor agonist to combat the urinary tract dysfunction, wherein the delta opioid receptor agonist has the formula:
- 16. The method according to claim 15, wherein the delta opioid receptor agonist is administered in a pharmaceutical composition comprising the delta opioid receptor agonist, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.
- 17. The method according to claim 16 wherein the composition is administered by an administration modality selected from the group consisting of oral, rectal, vaginal, topical, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, and intra-uterine administration.
- 18. The method according to claim 17, wherein the composition is administered in a unitary dose form.
- 19. The method according to claim 15, wherein the pharmaceutical composition for combating the urinary tract dysfunction, further comprises at least one additional active agent that combats the urinary tract dysfunction.
- 20. The method according to claim 19, wherein the active agent is selected from the group consisting of: an alpha-adrenergic agonist, an anticholinergic, an alpha-adrenergic antagonist and a tricyclic antidepressant.
- 21. The method according to claim 15, wherein the urinary tract dysfunction comprises urinary incontinence.
- 22. A pharmaceutical composition for combating a urinary tract dysfunction, comprising: a delta opioid receptor agonist in an effective amount to combat the urinary tract dysfunction; and a pharmaceutically acceptable carrier, wherein the delta opioid receptor agonist has the formula:
- 23. The pharmaceutical composition according to claim 22, further comprising at least one additional active agent that combats urinary tract dysfunctions.
- 24. The pharmaceutical composition according to claim 23, wherein the active agent is selected from the group consisting of: an alpha-adrenergic agonist, an anticholinergic, an alpha-adrenergic antagonist and a tricyclic antidepressant.
- 25. The pharmaceutical composition according to claim 22, wherein the delta opioid receptor agonist is administered to the subject in a dosage amount of from about 1 mg to about 50 mg per kilogram body weight per day.
- 26. The pharmaceutical composition according to claim 22, wherein the delta opioid receptor agonist is administered to the subject in a dosage amount of from about 10 ug to 500 mg per kg of body weight of the subject per day.
- 27. The pharmaceutical composition according to claim 22, wherein the delta opioid receptor agonist is administered to the subject in a dosage amount of from about 50 μg to 75 mg per kilogram of body weight per day.
- 28. The pharmaceutical composition according to claim 22, wherein the pharmaceutical composition is orally administrable.
- 29. A method for reducing the effects of urinary tract dysfunctions in a subject comprising: administering to the subject an effective amount of at least one delta opioid receptor agonist of the formula:
- 30. The method according to claim 29, wherein the delta opioid receptor agonist is selected from the group consisting of:
- 31. The method according to claim 29, wherein the delta opioid receptor agonist is combined with a pharmaceutically acceptable carrier.
- 32. The method according to claim 29, wherein the delta opioid receptor agonist is combined with an active agent used to treat urinary tract dysfunctions and is selected from the group consisting of: an alpha-adrenergic agonist, an anticholinergic, an alpha-adrenergic antagonist and a tricyclic antidepressant.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application No. 60/379,186 filed on May 9, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60379186 |
May 2002 |
US |